ReNetX Bio is a company that develops disease-modifying therapeutics to treat damage to the central nervous system (CNS). It provides the Nogo Receptor decoy as an orthogonal approach for patients to treat injuries in conditions such as spinal cord injury (SCI), stroke, and glaucoma. The company also offers small-molecule oral compounds.